ATE337014T1 - Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen - Google Patents

Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE337014T1
ATE337014T1 AT03388016T AT03388016T ATE337014T1 AT E337014 T1 ATE337014 T1 AT E337014T1 AT 03388016 T AT03388016 T AT 03388016T AT 03388016 T AT03388016 T AT 03388016T AT E337014 T1 ATE337014 T1 AT E337014T1
Authority
AT
Austria
Prior art keywords
mbl
pharmaceutical compositions
compositions
binding protein
variants
Prior art date
Application number
AT03388016T
Other languages
German (de)
English (en)
Inventor
Jesper Lund Larsen
Leif Kongerslev
Original Assignee
Natimmune As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natimmune As filed Critical Natimmune As
Application granted granted Critical
Publication of ATE337014T1 publication Critical patent/ATE337014T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03388016T 2002-03-15 2003-03-14 Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen ATE337014T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200200414 2002-03-15

Publications (1)

Publication Number Publication Date
ATE337014T1 true ATE337014T1 (de) 2006-09-15

Family

ID=27763313

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03388016T ATE337014T1 (de) 2002-03-15 2003-03-14 Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen

Country Status (11)

Country Link
US (1) US7462596B2 (https=)
EP (1) EP1344533B1 (https=)
JP (1) JP2005526084A (https=)
CN (1) CN1652813A (https=)
AT (1) ATE337014T1 (https=)
AU (1) AU2003215524A1 (https=)
DE (1) DE60307701T2 (https=)
DK (1) DK1344533T3 (https=)
ES (1) ES2271515T3 (https=)
PT (1) PT1344533E (https=)
WO (1) WO2003077937A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
ATE541582T1 (de) 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
TR201906789T4 (tr) 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
US7335633B2 (en) * 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
EP1618887A1 (en) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Clearance of polyols from the body
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
JP4744533B2 (ja) * 2004-12-30 2011-08-10 ドゥビエル カンパニー リミテッド 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法
WO2006108417A2 (en) * 2005-04-11 2006-10-19 Natimmune A/S Mannan-binding lectin (mbl) in the treatment of immunocompromised conditions associated with cancer
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
US20090304686A1 (en) * 2006-03-08 2009-12-10 Universotair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen
EP3050566B1 (en) * 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
US20120282285A1 (en) 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
CN102947341B (zh) 2010-01-19 2018-07-06 哈佛大学校长及研究员协会 用于病原体检测和治疗的工程化调理素
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
CN104284984B (zh) 2012-02-29 2017-10-13 哈佛大学校长及研究员协会 抗生素药敏性的快速测试
KR102339315B1 (ko) * 2012-06-18 2021-12-15 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
EP2976642A4 (en) 2013-03-15 2016-09-21 Harvard College METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3083658B1 (en) 2013-12-18 2019-05-08 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
CN110755601B (zh) * 2019-10-31 2023-06-23 云南康洲生物科技有限公司 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
WO2023055250A1 (en) * 2021-10-01 2023-04-06 University Of Belgrade Carbohydrate binding polypeptide of savalia savaglia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509089A (en) * 1998-06-10 2002-10-25 Statens Seruminstitut Affinity chromatography purification for production of mannan-binding lectin
US6429192B1 (en) * 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
EP1181038B1 (en) * 1999-05-14 2004-04-14 Steffen Thiel Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin

Also Published As

Publication number Publication date
AU2003215524A1 (en) 2003-09-29
US7462596B2 (en) 2008-12-09
EP1344533B1 (en) 2006-08-23
WO2003077937A1 (en) 2003-09-25
ES2271515T3 (es) 2007-04-16
CN1652813A (zh) 2005-08-10
DE60307701T2 (de) 2007-10-11
DK1344533T3 (da) 2007-01-08
DE60307701D1 (de) 2006-10-05
JP2005526084A (ja) 2005-09-02
PT1344533E (pt) 2007-01-31
EP1344533A1 (en) 2003-09-17
US20040006009A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
ATE337014T1 (de) Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen
IL203923A (en) Benzamide compounds, pharmaceutical compositions comprising them, use thereof in the preparation of medicaments and as medicaments and processes for the preparation of such compounds
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
EE200300370A (et) Atsüülitud 6,7,8,9-tetrahüdro-5H-bensotsükloheptenüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
BR0311313A (pt) Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase
CA2319308A1 (en) Pharmaceutical agents
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
ATE430555T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
DK0733046T3 (da) Benzoylguanidiner, deres fremstilling og anvendelse i medikamenter
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
IL170120A (en) 4,2,1 - Triazines, their use in the preparation of HIV treatment or prophylaxis drugs, containing pharmaceutical preparations and methods for their preparation
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
BRPI0412895A (pt) combinações de substáncias ativas fungicidas
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
AU2002348829A1 (en) Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2003020963A3 (en) Proteins in type 2 diabetes
NO20010940D0 (no) TAN-1057 derivater
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
WO2003050067A3 (fr) Analogues de la vitamine d
WO2003018535A3 (en) Novel aminobenzoephenones

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1344533

Country of ref document: EP

REN Ceased due to non-payment of the annual fee